Xenetic Biosciences (XBIO) EBITDA Margin (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly EBITDA Margin came in at 62.23% in Q1 2026, up 9663.0% YoY from 0.64% in Q1 2025, and up 23.46% on a QoQ basis from 81.3% in Q4 2025.
Xenetic Biosciences (XBIO) EBITDA Margin (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 13 years of EBITDA Margin data on file, last reported at 62.23% in Q1 2026.
- Quarterly EBITDA Margin rose 9663.0% year-over-year to 62.23% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 75.05% (up 7511.0% YoY) and the FY2025 annual result came in at 95.23%, up 7292.0% from the prior year.
- EBITDA Margin grew to 62.23% in Q1 2026, from 81.3% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 53.04% in Q3 2025 to a low of 644.83% in Q2 2022.
- A 5-year average of 203.4% and a median of 184.05% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin tumbled 25275 bps — and 2023, when it soared 46078 bps.
- Tracing XBIO's EBITDA Margin over 5 years: stood at 321.03% in 2022, then jumped by 42 bps to 186.87% in 2023, then increased by 9 bps to 169.41% in 2024, then jumped by 52 bps to 81.3% in 2025, then gained by 23 bps to 62.23% in 2026.
- The last three EBITDA Margin figures came in at 62.23% (Q1 2026), 81.3% (Q4 2025), and 53.04% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | -147.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -147.09% |
| Mar 31, 2026 | -62.23% |
| Dec 31, 2025 | -81.30% |
| Sep 30, 2025 | -53.04% |
| Jun 30, 2025 | -122.80% |
| Mar 31, 2025 | -158.85% |
| Dec 31, 2024 | -169.41% |
| Sep 30, 2024 | -81.32% |
| Jun 30, 2024 | -184.11% |
| Mar 31, 2024 | -248.31% |
| Dec 31, 2023 | -186.87% |
| Sep 30, 2023 | -187.62% |
| Jun 30, 2023 | -184.05% |
| Mar 31, 2023 | -151.06% |
| Dec 31, 2022 | -321.03% |
| Sep 30, 2022 | -204.66% |
| Jun 30, 2022 | -644.83% |
| Mar 31, 2022 | -416.39% |
| Dec 31, 2021 | -563.44% |
| Sep 30, 2021 | -393.97% |